» Articles » PMID: 21539734

Antiviral Activity of α-helical Stapled Peptides Designed from the HIV-1 Capsid Dimerization Domain

Overview
Journal Retrovirology
Publisher Biomed Central
Specialty Microbiology
Date 2011 May 5
PMID 21539734
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The C-terminal domain (CTD) of HIV-1 capsid (CA), like full-length CA, forms dimers in solution and CTD dimerization is a major driving force in Gag assembly and maturation. Mutations of the residues at the CTD dimer interface impair virus assembly and render the virus non-infectious. Therefore, the CTD represents a potential target for designing anti-HIV-1 drugs.

Results: Due to the pivotal role of the dimer interface, we reasoned that peptides from the α-helical region of the dimer interface might be effective as decoys to prevent CTD dimer formation. However, these small peptides do not have any structure in solution and they do not penetrate cells. Therefore, we used the hydrocarbon stapling technique to stabilize the α-helical structure and confirmed by confocal microscopy that this modification also made these peptides cell-penetrating. We also confirmed by using isothermal titration calorimetry (ITC), sedimentation equilibrium and NMR that these peptides indeed disrupt dimer formation. In in vitro assembly assays, the peptides inhibited mature-like virus particle formation and specifically inhibited HIV-1 production in cell-based assays. These peptides also showed potent antiviral activity against a large panel of laboratory-adapted and primary isolates, including viral strains resistant to inhibitors of reverse transcriptase and protease.

Conclusions: These preliminary data serve as the foundation for designing small, stable, α-helical peptides and small-molecule inhibitors targeted against the CTD dimer interface. The observation that relatively weak CA binders, such as NYAD-201 and NYAD-202, showed specificity and are able to disrupt the CTD dimer is encouraging for further exploration of a much broader class of antiviral compounds targeting CA. We cannot exclude the possibility that the CA-based peptides described here could elicit additional effects on virus replication not directly linked to their ability to bind CA-CTD.

Citing Articles

Modulation of HIV-1 capsid multimerization by sennoside A and sennoside B via interaction with the NTD/CTD interface in capsid hexamer.

Zhang D, Xu X, Zhou R, Fu Z Front Microbiol. 2023; 14:1270258.

PMID: 37817748 PMC: 10561090. DOI: 10.3389/fmicb.2023.1270258.


A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies.

Xu L, Wang C, Xu W, Xing L, Zhou J, Pu J Int J Mol Sci. 2023; 24(11).

PMID: 37298729 PMC: 10253554. DOI: 10.3390/ijms24119779.


Rational design of stapled antimicrobial peptides.

You Y, Liu H, Zhu Y, Zheng H Amino Acids. 2023; 55(4):421-442.

PMID: 36781451 DOI: 10.1007/s00726-023-03245-w.


A Broad-Spectrum Antiviral Molecule, Protoporphyrin IX, Acts as a Moderator of HIV-1 Capsid Assembly by Targeting the Capsid Hexamer.

Zhang D, Xie L, Xu X, Li Y, Xu X Microbiol Spectr. 2022; 11(1):e0266322.

PMID: 36475726 PMC: 9927277. DOI: 10.1128/spectrum.02663-22.


Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.

Monroe M, Wang H, Anderson C, Jia H, Flexner C, Cui H J Control Release. 2022; 348:1028-1049.

PMID: 35752254 PMC: 11022941. DOI: 10.1016/j.jconrel.2022.06.037.


References
1.
Moellering R, Cornejo M, Davis T, Del Bianco C, Aster J, Blacklow S . Direct inhibition of the NOTCH transcription factor complex. Nature. 2009; 462(7270):182-8. PMC: 2951323. DOI: 10.1038/nature08543. View

2.
Purdy J, Flanagan J, Ropson I, Rennoll-Bankert K, Craven R . Critical role of conserved hydrophobic residues within the major homology region in mature retroviral capsid assembly. J Virol. 2008; 82(12):5951-61. PMC: 2395126. DOI: 10.1128/JVI.00214-08. View

3.
Clore G, Gronenborn A . Three-dimensional structures of alpha and beta chemokines. FASEB J. 1995; 9(1):57-62. DOI: 10.1096/fasebj.9.1.7821760. View

4.
Naldini L, Blomer U, Gage F, Trono D, Verma I . Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996; 93(21):11382-8. PMC: 38066. DOI: 10.1073/pnas.93.21.11382. View

5.
Lazzarin A . Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother. 2005; 6(3):453-64. DOI: 10.1517/14656566.6.3.453. View